148 related articles for article (PubMed ID: 31789624)
1. Quantitative proteomic analysis reveals that Luks-PV exerts antitumor activity by regulating the key proteins and metabolic pathways in HepG2 cells.
Zhao CC; Yu WW; Qi YJ; Xu LF; Wang ZR; Qiang YW; Ma F; Ma XL
Anticancer Drugs; 2020 Mar; 31(3):223-230. PubMed ID: 31789624
[TBL] [Abstract][Full Text] [Related]
2. LukS-PV induces cell cycle arrest and apoptosis through p38/ERK MAPK signaling pathway in NSCLC cells.
Qiang Y; Ma F; Wang Z; Nie Z; Xu L; Ding P; Ma X
Biochem Biophys Res Commun; 2020 Jan; 521(4):846-852. PubMed ID: 31708104
[TBL] [Abstract][Full Text] [Related]
3. LukS-PV inhibits the proliferation of hepatocellular carcinoma cells by maintaining FOXO3 stability via the PI3K/AKT signaling pathway.
Nie Z; Shi L; Song K; Xu X; Ding P; Lu B; Wu G; Ma X
Cell Signal; 2022 Jul; 95():110357. PubMed ID: 35589047
[TBL] [Abstract][Full Text] [Related]
4. LukS-PV inhibits hepatocellular carcinoma cells migration by downregulating HDAC6 expression.
Xu X; Ding P; Shi L; Wu G; Ma X
BMC Cancer; 2022 Jun; 22(1):630. PubMed ID: 35676659
[TBL] [Abstract][Full Text] [Related]
5. LukS-PV induces apoptosis in acute myeloid leukemia cells mediated by C5a receptor.
Zhang P; Yu WW; Peng J; Xu LF; Zhao CC; Chang WJ; Ma XL
Cancer Med; 2019 May; 8(5):2474-2483. PubMed ID: 30955242
[TBL] [Abstract][Full Text] [Related]
6. LukS-PV induces mitochondrial-mediated apoptosis and G0/G1 cell cycle arrest in human acute myeloid leukemia THP-1 cells.
Bu S; Xie Q; Chang W; Huo X; Chen F; Ma X
Int J Biochem Cell Biol; 2013 Aug; 45(8):1531-7. PubMed ID: 23702031
[TBL] [Abstract][Full Text] [Related]
7. LukS-PV-Regulated MicroRNA-125a-3p Promotes THP-1 Macrophages Differentiation and Apoptosis by Down-Regulating NF1 and Bcl-2.
Sun XX; Zhang SS; Dai CY; Peng J; Pan Q; Xu LF; Ma XL
Cell Physiol Biochem; 2017; 44(3):1093-1105. PubMed ID: 29179212
[TBL] [Abstract][Full Text] [Related]
8. LukS-PV, a component of Panton-Valentine leukocidin, exerts potent activity against acute myeloid leukemia in vitro and in vivo.
Shan W; Bu S; Zhang C; Zhang S; Ding B; Chang W; Dai Y; Shen J; Ma X
Int J Biochem Cell Biol; 2015 Apr; 61():20-8. PubMed ID: 25601295
[TBL] [Abstract][Full Text] [Related]
9. LukS-PV induces differentiation by activating the ERK signaling pathway and c-JUN/c-FOS in human acute myeloid leukemia cells.
Dai C; Zhang C; Sun X; Pan Q; Peng J; Shen J; Ma X
Int J Biochem Cell Biol; 2016 Jul; 76():107-14. PubMed ID: 27102414
[TBL] [Abstract][Full Text] [Related]
10. Identification of the essential amino acid residues in lukS for the hemolytic activity of staphylococcal leukocidin towards rabbit erythrocytes.
Nariya H; Shimatani A; Tomita T; Kamio Y
Biosci Biotechnol Biochem; 1997 Dec; 61(12):2095-9. PubMed ID: 9438990
[TBL] [Abstract][Full Text] [Related]
11. LukS-PV Inhibits Hepatocellular Carcinoma Cells Migration via the TNNC1/PI3K/AKT Axis.
Ma F; Wang Z; Qiang Y; Xu L; Ding P; Wang Y; Ma X
Onco Targets Ther; 2020; 13():10221-10230. PubMed ID: 33116603
[TBL] [Abstract][Full Text] [Related]
12. The lipid homeostasis regulation study of arenobufagin in zebrafish HepG2 xenograft model and HepG2 cells using integrated lipidomics-proteomics approach.
Zhao LJ; Zhao HY; Wei XL; Guo FF; Wei JY; Wang HJ; Yang J; Yang ZG; Si N; Bian BL
J Ethnopharmacol; 2020 Oct; 260():112943. PubMed ID: 32422359
[TBL] [Abstract][Full Text] [Related]
13. Is LukS-PV a novel experimental therapy for leukemia?
Shan W; Ma X; Deng F
Gene; 2017 Feb; 600():44-47. PubMed ID: 27916717
[TBL] [Abstract][Full Text] [Related]
14. Construction of a LukS-PV mutant of a staphylococcal Panton-Valentine leukocidin component having a high LukS-like function.
Shimatani A; Kaneko J; Tomita T; Kamio Y
Biosci Biotechnol Biochem; 1999 Oct; 63(10):1828-30. PubMed ID: 10586512
[TBL] [Abstract][Full Text] [Related]
15. LukS-PV Inhibits Hepatocellular Carcinoma Progression by Downregulating HDAC2 Expression.
Wang Z; Yu W; Qiang Y; Xu L; Ma F; Ding P; Shi L; Chang W; Mei Y; Ma X
Mol Ther Oncolytics; 2020 Jun; 17():547-561. PubMed ID: 32637573
[TBL] [Abstract][Full Text] [Related]
16. Engineering of the LukS-PV and LukF-PV subunits of Staphylococcus aureus Panton-Valentine leukocidin for diagnostic and therapeutic applications.
Okolie CE; Cockayne A; Penfold C; James R
BMC Biotechnol; 2013 Nov; 13():103. PubMed ID: 24252611
[TBL] [Abstract][Full Text] [Related]
17. Proteomic analysis of apoptosis induction by lariciresinol in human HepG2 cells.
Ma ZJ; Wang XX; Su G; Yang JJ; Zhu YJ; Wu YW; Li J; Lu L; Zeng L; Pei HX
Chem Biol Interact; 2016 Aug; 256():209-19. PubMed ID: 27417256
[TBL] [Abstract][Full Text] [Related]
18. Structurally designed attenuated subunit vaccines for S. aureus LukS-PV and LukF-PV confer protection in a mouse bacteremia model.
Karauzum H; Adhikari RP; Sarwar J; Devi VS; Abaandou L; Haudenschild C; Mahmoudieh M; Boroun AR; Vu H; Nguyen T; Warfield KL; Shulenin S; Aman MJ
PLoS One; 2013; 8(6):e65384. PubMed ID: 23762356
[TBL] [Abstract][Full Text] [Related]
19. Bacterial two-component and hetero-heptameric pore-forming cytolytic toxins: structures, pore-forming mechanism, and organization of the genes.
Kaneko J; Kamio Y
Biosci Biotechnol Biochem; 2004 May; 68(5):981-1003. PubMed ID: 15170101
[TBL] [Abstract][Full Text] [Related]
20. The interaction of Staphylococcus aureus bi-component gamma-hemolysins and leucocidins with cells and lipid membranes.
Ferreras M; Höper F; Dalla Serra M; Colin DA; Prévost G; Menestrina G
Biochim Biophys Acta; 1998 Nov; 1414(1-2):108-26. PubMed ID: 9804914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
